07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Iterum Therapeutics plc ITRM recently announced updates from the meeting of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) that discussed its new drug application (NDA) for oral ...

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday? Wall Street slumped into negative territory late in the week as renewed fears over ...

07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant ...

Iterum Therapeutics (NASDAQ:ITRM) is scheduled to announce Q4 earnings results on Friday, February 7th, before market open. The consensus EPS Estimate is -$0.24 (+70.4% Y/Y)Over the last 2 years ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Short interest in Iterum Therapeutics PLC (NASDAQ:ITRM) decreased during the last reporting period, falling from 1.58M to 1.53M. This put 4.53% of the company's publicly available shares short.